



AGENDA FOR THE 16TH ACCELERATE PAEDIATRIC STRATEGY FORUM

B7H3 Targeting in Paediatric Malignancies

29-30 OCT
2026

La Terrasse de Paris
45 Rue Jussieu, Paris
& Online

HOSTED AND SUPPORTED BY:

**GUSTAVE
ROUSSY**
CANCER CAMPUS
GRAND PARIS


Paris Kids
Cancer

DAY 1: 29 OCT

9:45 - 10:30	Registration and welcome coffee
10:30 - 10:45	Welcome and Introduction <i>Nicole Scobie, ACCELERATE Chair; Franca Ligas, EMA; Kristin Wessel, FDA; Gilles Vassal, ACCELERATE Scientific Committee Chair</i>
10:45 - 13:00	Setting the scene <i>Chair: Lynley Marshall, The Royal Marsden Hospital & The Institute of Cancer Research</i>
10:45 - 11:15	• Understanding B7H3 biology in cancer and normal cells - <i>John Anderson, UCL</i>
11:15 - 11:35	• Expression pattern in pediatric malignancies - <i>Rebecca Epperly, St. Jude</i>
11:35 - 11:50	• Landscape of B7H3 targeting assets in development - <i>Kristin Wessel, FDA</i>
11:50 - 13:00	• Panel discussion: – Which pediatric malignancies to target? – Should patients be selected or not? <i>Panelists: John Anderson, UCL; Rebecca Epperly, St. Jude; Kristin Wessel, FDA; Julia Glade-Bender, MSKCC; Veronique Minard-Collin, Gustave Roussy; Patricia Blanc, Imagine For Margo</i>
13:00 - 14:00	Lunch
14:00 - 15:30	B7H3 Cell Therapies <i>Chair: Claudia Rossig, University of Munster</i>
14:00 - 14:15	• Overview of B7H3 CAR T cells development - <i>Stephen Gottschalk, St Jude (remote)</i>
14:15 - 14:45	• Clinical data in pediatric extracranial and CNS malignancies - <i>Nicholas Vitanza, Seattle Children's (remote)</i>
14:45 - 15:05	• The LifeArc project - <i>Robbie Majzner, Dana-Farber; Andy Pearson, LifeArc (remote)</i>
15:05 - 15:45	• Q&A and Discussion: How to harmonize B7H3 CART cells development
15:45 - 16:15	Coffee break
16:15 - 18:30	Strategies to improve efficacy of B7H3 cell therapies <i>Chair: Claudia Rossig, University of Munster</i>
16:15 - 16:30	• B7-H3-CAR T-cell therapy for pediatric solid and brain tumors: insights from clinical translation - <i>Chris Derenzo, St. Jude</i>
16:30 - 16:45	• BC2 Peds: A B7H3 CAR Incorporating CXCR2 to Enhance Tumor Trafficking - <i>Navin Pinto, Children's Colorado</i>
16:45 - 17:15	• Seattle program - <i>Nicholas Vitanza, Seattle Children's (remote)</i>
17:15 - 17:30	• Stanford program - <i>Sneha Ramakrishna, Stanford Medicine Seattle program</i>

17:30 - 18:30	• Panel discussion: How to improve efficacy of B7H3 CART? Panelists: Stephen Gottchalk, St. Jude; Nicholas Vitanza, Seattle Children's (remote); Chris Derenzo, St. Jude; Navin Pinto, Children's Colorado; Robbie Mazjner, Dana-Farber; John Anderson, UCL; Amaury Leruste, Institut Curie; Giovanni Lesa, EMA; Amy Barone, FDA; Vickie Buenger, CAC2
18:30	End of day 1
19:30	Social Dinner (sign-up required) Le Procope - 13 rue de l'Ancienne Comédie, 75006 Paris Access: Metro line 10 direction Boulogne to Odéon

DAY 2: 30 OCT

9:30 - 10:00	Welcome coffee
10:00 - 12:00	B7H3 targeting assets in development Chair: Lia Gore, Children's Colorado
10:00 - 10:15	• Overview of industry B7H3 compounds and pediatric challenges - Gilles Vassal, ACCELERATE Scientific Committee Chair
10:15 - 10:30	• Ifinatamab deruxtecan and DS557 Ab. - John Chung, Daiichi Sankyo; Scott Diede, MSD
10:30 - 10:45	• YL201 ADC – Roche - Beate Wulff / Francis Mussai, Roche
10:45 - 11:00	• Risvutaturg rezetecan - GSK - Thierry Horner, GSK
11:00 - 12:00	• Panel discussion Panelists: John Chung, Daiichi Sankyo; Scott Diede, MSD; Beate Wulff, Roche; Francis Mussai, Roche; Thierry Horner, GSK; Amy Barone, FDA; Sylvie Benchetrit, EMA; Nicole Scobie, ACCELERATE Chair; Pablo Berlanga, Gustave Roussy; Lia Gore, Children's Colorado; Lu Xie, Peking University People's Hospital (remote)
12:00 - 13:00	Lunch
13:00 - 13:15	Advocates insight - Susan Weiner, Children's Cancer Cause
13:15 - 14:15	Strategic discussion Chair: Gilles Vassal, ACCELERATE Scientific Committee Chair How to facilitate prioritization of B7H3 compounds for pediatric development? Panelists: Steven DuBois, Dana-Farber; Pablo Berlanga, Gustave Roussy; Franca Ligas, EMA; Claudia Rossig, Munster; Susan Weiner, Children's Cancer Cause; Amy Barone, FDA; Scott Diede, MSD
14:15 - 14:30	Wrap up
14:30	End of day 2

WE GRATEFULLY ACKNOWLEDGE THE GENEROUS SUPPORT OF OUR ACCELERATE PARTNERS:

STRATEGIC PARTNER:



CHAMPION PARTNERS:



MISSION PARTNERS:



COMMUNITY PARTNERS:



FORUM SUPPORTERS:

